ESPE Abstracts (2014) 82 P-D-2-2-427

ESPE2014 Poster Category 2 Growth Hormone (1) (13 abstracts)

Effects and Safety of Recombinant Human GH in GH Deficient Children with Rathke Cyst

Liyang Liang , Lina Zhang , Zhe Meng , Hui Ou , Zhanwen He , Lele Hou , Dongfang Li , Pinggan Li & Xiangyang Luo

Department of Pediatrics, Sun Yat-sen Memorial Hospital, Guangzhou, China

Objective: To assess the effects and safety of recombinant human GH (rhGH) in GH deficient (GHD) children with Rathke cyst.

Methods: The clinical data of 12 GHD children aged from 5–12 years old, whose radiologic diagnosis showed Rathke cyst during Jan 2010–Dec 2012 in our hospital, were analyzed retrospectively. rhGH was given subcutaneously to each enrolled child with a night dose of 0.1 IU/kg six to seven times a week for 12–30 months. The serum biochemical indices as well as endocrine hormone level were detected regularly. The clinical data before and after treatment were compared, including height, weight, growth velocity, height SDs, IGF1, bone age and the magnetic resonance imaging result.

Results: With rhGH treatment, a significant increase(P<0.01) of growth velocity in all 12 children, from 4.06±0.61 to 9.86±4.01 cm, was observed in the first 12 months. Meanwhile the height SDS increased obviously from −3.31±1.47 to −2.83±1.36 (P<0.01). In addition, IGF1 rose from (186.73±73.32) μg/l to (436.78±208.60) μg/l (P<0.01), with IGFBP3 from (4.32±0.96) mg/l to (5.63±1.45) mg/l. The peak values of both IGF1 and IGFBP3 were within normal limits. During the treatment and the follow-up period, the biochemical indices were normal and the volumes of the Rathke cysts didn’t increase.

Conclusion: The treatment of low level rhGH in GHD children with Rathke cyst was demonstrated effective in this study. Moreover, GH treatment is safe when fully evaluated and closely monitored.

Article tools

My recent searches

No recent searches.